The abstract is read at the publisher; the summary is JClub's.
Activated RET signaling in patient-derived medullary thyroid cancer cells is linked to increased osteoprotegerin (OPG) expression, reduced osteoclast differentiation, and osteoblastic bone lesions in mouse femurs.
- Why it matters: Bone metastases in medullary thyroid cancer drive high mortality, with ~50% survival at 5 years, yet the mechanism connecting tumor signaling to osteoblastic lesions is unclear.
- What they did: Using RET C634W mutant TT and RET M918T mutant MZCRC1 cells, the study tested how RET activation, RET knockdown, and pharmacological RET inhibition affect OPG, osteoclast differentiation, and tumor burden in MTC-bearing mouse femurs.
- The result: Circulating OPG rises in patients with MTC and MTC bone metastases and is associated with poor overall survival; RET inhibition in mice and lower OPG with multi-kinase inhibitors suggest OPG may serve as a biomarker.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.